Targeting Alternative Splicing as a Potential Therapy for Episodic Ataxia Type 2

Fanny Jaudon1, Simona Baldassari2, Ilaria Musante2,3

  • 1Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.

Biomedicines
|September 9, 2020
PubMed
Summary

Episodic ataxia type 2 (EA2) is a neurological disorder caused by mutations in the CACNA1A gene. Splicing-based strategies offer a promising new therapeutic approach for EA2, potentially improving upon existing treatments.